Synergistic effects of histone deacetylase inhibitor in combination with mTOR inhibitor in the treatment of prostate carcinoma

International Journal of Molecular Medicine

Volumn 31, Issue 2, 2013, Pages 339-346

  Thelen, Paul ^a   Krahn, Lisa ^b   Bremmer, Felix ^a   Strauss, Arne ^a   Brehm, Ralph ^b   Loertzer, Hagen ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

Anti androgen therapy; Castration resistant prostate cancer; Cell survival signaling; Preclinical study

Indexed keywords

MESSENGER RNA; SOMATOMEDIN BINDING PROTEIN 3; TEMSIROLIMUS; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CELL STRAIN LNCAP; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOLOGY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; TUMOR VOLUME; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; HISTONE DEACETYLASE INHIBITORS; HUMANS; MALE; MICE; MICE, NUDE; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; SIROLIMUS; TOR SERINE-THREONINE KINASES; VALPROIC ACID;

EID: 84873208213     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.1221     Document Type: Article

References (50)

1. Börgermann C, Loertzer H, Luboldt HJ, et al: PSA - Quo vadis? Urologe A 48: 1012-1014, 2009 (In German).
2. Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512, 2004.
3. Centenera MM, Harris JM, Tilley WD and Butler LM: The contribution of different androgen receptor domains to receptor dimerization and signaling. Mol Endocrinol 22: 2373-2382, 2008.
4. Knudsen KE and Penning TM: Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab 21: 315-324, 2010.
5. Wang L, Zou X, Berger AD, et al: Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. Am J Transl Res 1: 62-71, 2009.
6. Weichert W, Röske A, Gekeler V, et al: Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 98: 604-610, 2008.
7. Halkidou K, Gaughan L, Cook S, et al: Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59: 177-189, 2004.
8. Xu WS, Parmigiani RB and Marks PA: Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26: 5541-5552, 2007.
9. Göttlicher M, Minucci S, Zhu P, et al: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20: 6969-6978, 2001.
10. Xia Q, Sung J, Chowdhury W, et al: Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res 66: 7237-7244, 2006.
11. Thelen P, Schweyer S, Hemmerlein B, et al: Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells. Int J Oncol 24: 25-31, 2004.
12. Stettner M, Kaulfuss S, Burfeind P, et al: The relevance of estrogen receptor-beta expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment. Mol Cancer Ther 6: 2626-2633, 2007.
13. Yuan R, Kay A, Berg WJ and Lebwohl D: Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2: 45, 2009.
14. Li J, Yen C, Liaw D, et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947, 1997.
15. Steck PA, Pershouse MA, Jasser SA, et al: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15: 356-362, 1997.
16. Jiang BH and Liu LZ: PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 102: 19-65, 2009.
17. Kremer CL, Klein RR, Mendelson J, et al: Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 66: 1203-1212, 2006.
18. Pollak M: Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8: 915-928, 2008.
19. Han J, Jogie-Brahim S, Harada A and Oh Y: Insulin-like growth factor-binding protein-3 suppresses tumor growth via activation of caspase-dependent apoptosis and cross-talk with NF-κB signaling. Cancer Lett 307: 200-210, 2011.
20. Franklin SL, Ferry RJ Jr and Cohen P: Rapid insulin-like growth factor (IGF)-independent effects of IGF binding protein-3 on endothelial cell survival. J Clin Endocrinol Metab 88: 900-907, 2003.
21. Igawa T, Lin FF, Lee MS, et al: Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate 50: 222-235, 2002.
22. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
23. Gerdes J, Lemke H, Baisch H, et al: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710-1715, 1984.
24. Scholzen T and Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol 182: 311-322, 2000.
25. Yuan PX, Huang LD, Jiang YM, et al: The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem 276: 31674-31683, 2001.
26. Blaheta RA and Cinatl J Jr: Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev 22: 492-511, 2002.
27. Cheng J, Lee EJ, Madison LD and Lazennec G: Expression of estrogen receptor β in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. FEBS Lett 566: 169-172, 2004.
28. Horvath LG, Henshall SM, Lee CS, et al: Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res 61: 5331-5335, 2001.
29. Latil A, Bièche I, Vidaud D, et al: Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res 61: 1919-1926, 2001.
30. Pasquali D, Rossi V, Esposito D, et al: Loss of estrogen receptor beta expression in malignant human prostate cells in primary cultures and in prostate cancer tissues. J Clin Endocrinol Metab 86: 2051-2055, 2001.
31. Pasquali D, Staibano S, Prezioso D, et al: Estrogen receptor beta expression in human prostate tissue. Mol Cell Endocrinol 178: 47-50, 2001.
32. Wedel S, Hudak L, Seibel JM, et al: Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001. Life Sci 88: 418-424, 2011.
33. Chen S, Xu Y, Yuan X, et al: Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Proc Natl Acad Sci USA 103: 15969-15974, 2006.
34. Azim H, Azim HA Jr and Escudier B: Targeting mTOR in cancer: renal cell is just a beginning. Target Oncol 5: 269-280, 2010.
35. Zhang W, Zhu J, Efferson CL, et al: Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer. Cancer Res 69: 7466-7472, 2009.
36. Fung AS, Wu L and Tannock IF: Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts. Clin Cancer Res 15: 5389-5395, 2009.
37. Thompson IM Jr, Leach RJ and Ankerst DP: Prostate cancer detection: a view of the future. Eur Urol 59: 191-193, 2011.
38. Moschos SJ and Mantzoros CS: The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology 63: 317-332, 2002.
39. Jogie-Brahim S, Feldman D and Oh Y: Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr Rev 30: 417-437, 2009.
40. Marelli MM, Moretti RM, Procacci P, et al: Insulin-like growth factor-I promotes migration in human androgen-independent prostate cancer cells via the ανβ3 integrin and PI3-K/Akt signaling. Int J Oncol 28: 723-730, 2006.
41. Goya M, Miyamoto S, Nagai K, et al: Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors. Cancer Res 64: 6252-6258, 2004.
42. Wen Y, Hu MC, Makino K, et al: HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 60: 6841-6845, 2000.
43. Manin M, Baron S, Goossens K, et al: Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells. Biochem J 366: 729-736, 2002.
44. Rowlands MA, Holly JM, Hamdy F, et al: Serum insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancer. Cancer Causes Control 23: 347-354, 2012.
45. Shabbeer S, Kortenhorst MS, Kachhap S, et al: Multiple molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo. Prostate 67: 1099-1110, 2007.
46. Yagi Y, Fushida S, Harada S, et al: Effects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a scirrhous gastric cancer cell line. J Exp Clin Cancer Res 29: 149, 2010.
47. Machado MC, Bellodi-Privato M, Kubrusly MS, et al: Valproic acid inhibits human hepatocellular cancer cells growth in vitro and in vivo. J Exp Ther Oncol 9: 85-92, 2011.
48. Morgan TM, Pitts TE, Gross TS, et al: RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. Prostate 68: 861-871, 2008.
49. Schayowitz A, Sabnis G, Goloubeva O, et al: Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR. Br J Cancer 103: 1001-1007, 2010.
50. Corcoran NM, Costello AJ and Hovens CM: Interfering with cell-survival signalling as a treatment strategy for prostate cancer. BJU Int 97: 1149-1153, 2006.